Beth Brooks

Vancouver, BC V6T1Z4, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Exploring and Overcoming Challenges for Efficient Audiological Testing in Children Under 5 Years of Age-Screening with Otoacoustic Emissions.

Exploring and Overcoming Challenges for Efficient Audiological Testing in Children Under 5 Years of Age-Screening with Otoacoustic Emissions.

Journal: Audiology research

Published: March 24, 2026

Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.

Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 05, 2025

TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.

TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.

Journal: The Journal of pharmacology and experimental therapeutics

Published: July 08, 2024

Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.

Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.

Journal: Therapeutic drug monitoring

Published: November 23, 2022

Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.

Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.

Journal: Therapeutic drug monitoring

Published: August 29, 2022

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.

Journal: JAMA oncology

Published: August 12, 2021

Appraising the need for audiological assessment before autism spectrum disorder referral.

Appraising the need for audiological assessment before autism spectrum disorder referral.

Journal: Paediatrics & child health

Published: May 21, 2021

The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Journal: Cancer

Published: March 30, 2021

Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.

Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.

Journal: The Lancet. Child & adolescent health

Published: October 30, 2020

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Journal: Clinical pharmacology and therapeutics

Published: March 01, 2019

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Journal: The Lancet. Oncology

Published: August 24, 2018

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 26, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026